Accelerating Therapeutic DiscoveryTM

Partnerships

AGTC

ALNY

arrowhead

BU

Inhibrx

NCATS

UMASS


About The Alpha-1 Project

The Alpha-1 Project (TAP) is a wholly owned subsidiary of the Alpha-1 Foundation singularly focused on bridging the gap between clinical trials and commercialization of therapies for the elimination of Chronic Obstructive Pulmonary Disease (COPD) and liver disease caused by Alpha-1 Antitrypsin Deficiency (Alpha-1).

Learn More

Latest News

Scientific founders who originated the miRNA mediated “silence and replace” approach take on Alpha-1 and ALS US ...
Posted on January 07, 2019
Based on the most recent data from the ADVANCE clinical trial, the Company is reviewing the learnings from the study, notably...
Posted on December 17, 2018

General Contact

The Alpha-1 Project

3300 Ponce de Leon Boulevard
Coral Gables, FL 33134
Phone: 305-648-9541
Toll-free: 888-920-0002
Fax: 305-441-2110
Email: info@thealpha-1project.com